相关实验视频

Updated: Jun 22, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

关于RAF激酶及其抑制剂的概述 (2019-2023)

Omar Hashem¹, Afnan I Shahin², Manar A Al Hindawi³

¹Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates.

European journal of medicinal chemistry

|July 2, 2024

概括

新的RAF激酶抑制剂对于癌症治疗至关重要,提供更好的疗效和降低毒性. 本综述详细介绍了小分子抑制剂的最新进展,重点关注化学结构和治疗潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药用化学医学化学

背景情况:

雷夫基因酶调节关键细胞过程,它们的失调驱动癌症的发展.
RAF 激酶抑制剂是重要的抗癌剂,向癌细胞增殖和血管生成.
现有的治疗方法面临毒性和耐药性的挑战,需要新的治疗策略.

研究的目的:

从2019年到2023年,审查和分析报告在专利和文献中的RAF激酶抑制剂.
突出化学结构,生物化学概况以及这些抑制剂的当前状态.
检查链区域的相互作用,并讨论克服阻力和提高安全性的策略.

主要方法:

关于RAF激酶抑制剂的综合文献和专利搜索 (2019-2023年).
分析化学结构,生物化学数据和临床试验信息.
详细检查链区域结合相互作用和阻力机制.

主要成果:

根据化学支架和作用机制识别和分类各种RAF激酶抑制剂.
突出了关键的结构特征,包括链结合部分和结合模式.
总结了审查的抑制剂的疗效,安全性概况和发育状态.

结论:

最近的RAF激酶抑制剂在癌症治疗中表现有前途,目前正在进行的研究重点是提高疗效和安全性.
克服耐药性和最大限度地降低细胞毒性是通过全RAF抑制剂和组合疗法等新策略解决的关键挑战.
进一步开发对于优化RAF激酶抑制剂至关重要,以改善各种癌症类型的临床结果.

关键词:

这是一种抗癌药物.部地区部地区异构体的异构体形式在RAF中使用RAF激酶抑制剂.在RAF中发生酶突变和二元化.电阻电阻电阻电阻电阻电阻英国皇家空军的结构和功能

更多相关视频

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...